Abselion

Series-A
abselion.com Biotech & Healthcare Cambridge, United Kingdom
Total Funding $8.9M
Latest Round $8.9M Series-A
Last Announced Dec 4, 2024
Investors 9 Backers
Decision Makers 6 Available

About Abselion

Amperia by Abselion enables simple, reliable biomolecule quantification across biologics workflows. Quantify antibodies, AAV capsids and His-tagged proteins.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Cambridge, United Kingdom
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website abselion.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile @AbselionX (8 followers)
LinkedIn Corporate Company Profile

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised $8,860,000 · Series-A

    Backed by M Ventures

Investors & Backers

9
M Ventures
Lead
BioProcess360 Partners
Business Growth Fund
New Ground Ventures
Parkwalk Advisors
R42 Group
Swiss Health Angels
University of Cambridge Enterprise
UNTITLED

Funding History

1 Round
Series-A equity · Dec 4, 2024

Round backers: M Ventures

Founders & Leadership

2

Christoph v. Bieberstein

Founder

Work email & phone locked Unlock →

Ruizhi Wang

Founder & CEO

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts